文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Clinical characteristics and overall survival prognostic nomogram for metaplastic breast cancer.

作者信息

Zheng Caihong, Fu Chengbin, Wen Yahui, Liu Jiameng, Lin Shunguo, Han Hui, Han Zhonghua, Xu Chunsen

机构信息

The Graduate School of Fujian Medical University, Fuzhou, Fujian, China.

Department of Breast Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, China.

出版信息

Front Oncol. 2023 Mar 2;13:1030124. doi: 10.3389/fonc.2023.1030124. eCollection 2023.


DOI:10.3389/fonc.2023.1030124
PMID:36937402
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10018193/
Abstract

BACKGROUND: Metaplastic breast cancer (MBC) is a rare breast tumor and the prognostic factors for survival in patients still remain controversial. This study aims to develop and validate a nomogram to predict the overall survival (OS) of patients with MBC. METHODS: We searched the Surveillance, Epidemiology, and End Results (SEER) database for data about patients including metaplastic breast cancer and infiltrating ductal carcinoma (IDC) from 2010 to 2018. The survival outcomes of patients between MBC and IDC were analyzed and compared with the Kaplan-Meier (KM) method. MBC patients were randomly allocated to the training set and validation I set by a ratio of eight to two. Meanwhile, the performance of this model was validated again by the validation II set, which consisted of MBC patients from the Union Hospital of Fujian Medical University between 2010 and 2018. The independent prognostic factors were selected by univariate and multivariate Cox regression analyses. The nomogram was constructed to predict individual survival outcomes for MBC patients. The discriminative power, calibration, and clinical effectiveness of the nomogram were evaluated by the concordance index (C-index), the receiver operating characteristic (ROC) curve, and the decision curve analysis (DCA). RESULTS: MBC had a significantly higher T stage (T2 and above accounting for 75.1% vs 39.9%), fewer infiltrated lymph nodes (N0 accounted for 76.2% vs 67.7%), a lower proportion of ER (22.2% vs 81.2%), PR (13.6% vs 71.4%), and HER-2(6.7% vs 17.7%) positive, radiotherapy(51.6% vs 58.0%) but more chemotherapy(67.5% vs 44.7%), and a higher rate of mastectomy(53.2% vs 36.8%), which was discovered when comparing the clinical baseline data between MBC and IDC. Age at diagnosis, T, N, and M stage, as well as surgery and radiation treatment, were all significant independent prognostic factors for overall survival (OS). In the validation I cohort, the nomogram's C-index (0.769 95% CI 0.710 -0.828) was indicated to be considerably higher than the standard AJCC model's (0.700 95% CI 0.644 -0.756). Nomogram's great predictive capability capacity further was supported by the comparatively high C-index of the validation II sets (0.728 95%CI 0.588-0.869). CONCLUSIONS: Metaplastic breast cancer is more aggressive, with a worse clinical prognosis than IDC. This nomogram is recommended for patients with MBC, both American and Chinese, which can help clinicians make more accurate individualized survival analyses.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/415c/10018193/cbde14da62bf/fonc-13-1030124-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/415c/10018193/eb9560a1c831/fonc-13-1030124-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/415c/10018193/9d769724a45e/fonc-13-1030124-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/415c/10018193/9eef2f9811f5/fonc-13-1030124-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/415c/10018193/c52f87344537/fonc-13-1030124-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/415c/10018193/98bacabc721d/fonc-13-1030124-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/415c/10018193/6fa6567abf08/fonc-13-1030124-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/415c/10018193/a0b73c0ca8b0/fonc-13-1030124-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/415c/10018193/2d4ae3536edf/fonc-13-1030124-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/415c/10018193/cbde14da62bf/fonc-13-1030124-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/415c/10018193/eb9560a1c831/fonc-13-1030124-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/415c/10018193/9d769724a45e/fonc-13-1030124-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/415c/10018193/9eef2f9811f5/fonc-13-1030124-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/415c/10018193/c52f87344537/fonc-13-1030124-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/415c/10018193/98bacabc721d/fonc-13-1030124-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/415c/10018193/6fa6567abf08/fonc-13-1030124-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/415c/10018193/a0b73c0ca8b0/fonc-13-1030124-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/415c/10018193/2d4ae3536edf/fonc-13-1030124-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/415c/10018193/cbde14da62bf/fonc-13-1030124-g009.jpg

相似文献

[1]
Clinical characteristics and overall survival prognostic nomogram for metaplastic breast cancer.

Front Oncol. 2023-3-2

[2]
A nomogram for predicting the risk of male breast cancer for overall survival.

Front Oncol. 2023-8-4

[3]
Nomogram for predicting preoperative regional lymph nodes metastasis in patients with metaplastic breast cancer: a SEER population-based study.

BMC Cancer. 2021-5-17

[4]
Establishment of Prognostic Nomogram for Male Breast Cancer Patients: A Surveillance, Epidemiology and End Results Database Analysis.

Cancer Control. 2024

[5]
Development and Validation of a Nomogram for Predicting Survival in Male Patients With Breast Cancer.

Front Oncol. 2019-5-14

[6]
Comparison of the prognosis of medullary breast carcinoma and invasive ductal carcinoma: a SEER-based study.

Transl Cancer Res. 2024-1-31

[7]
Clinical characteristics and overall survival prognostic nomogram for invasive cribriform carcinoma of breast: a SEER population-based analysis.

BMC Cancer. 2021-2-16

[8]
A prognostic nomogram for overall survival in male breast cancer with histology of infiltrating duct carcinoma after surgery.

PeerJ. 2019-10-14

[9]
A nomogram model based on the number of examined lymph nodes-related signature to predict prognosis and guide clinical therapy in gastric cancer.

Front Immunol. 2022

[10]
Establishment of prognostic model for postoperative patients with metaplastic breast cancer: Based on a retrospective large data analysis and Chinese multicenter study.

Front Genet. 2022-8-25

引用本文的文献

[1]
Survival outcomes after systemic treatment of high-grade triple-negative metaplastic breast cancer versus triple-negative breast cancer of no special type.

Virchows Arch. 2025-8-22

[2]
TNMpBC-NeoBCSS model: a breast cancer specific survival prediction model for triple-negative metaplastic breast carcinoma patients with neoadjuvant therapy.

Sci Rep. 2025-3-11

[3]
Novel models based on machine learning to predict the prognosis of metaplastic breast cancer.

Breast. 2025-2

[4]
Treatment outcomes and prognostic factors in nonmetastatic metaplastic breast cancer patients: a multicenter retrospective cohort study.

Acta Oncol. 2024-8-4

[5]
Case report: Successful treatment of a rare HER2-positive advanced breast squamous cell carcinoma.

Front Pharmacol. 2024-2-22

本文引用的文献

[1]
Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification.

Cancer Res. 2022-4-15

[2]
The Effect of Post-Mastectomy Radiotherapy in Patients With Metaplastic Breast Cancer: A Propensity Score-Matched Analysis of the SEER Database.

Front Oncol. 2022-1-12

[3]
A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609).

Clin Cancer Res. 2022-1-15

[4]
Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial.

Ann Oncol. 2021-12

[5]
The different outcomes between breast-conserving surgery plus radiotherapy and mastectomy in metaplastic breast cancer: A population-based study.

PLoS One. 2021

[6]
Adjuvant Olaparib for Patients with - or -Mutated Breast Cancer.

N Engl J Med. 2021-6-24

[7]
A nomogram for predicting pancreatic mucinous cystic neoplasm and serous cystic neoplasm.

Abdom Radiol (NY). 2021-8

[8]
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

CA Cancer J Clin. 2021-5

[9]
Survival Outcomes for Metaplastic Breast Cancer Differ by Histologic Subtype.

Ann Surg Oncol. 2021-8

[10]
A comprehensive overview of metaplastic breast cancer: clinical features and molecular aberrations.

Breast Cancer Res. 2020-11-4

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索